Cargando…

Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases

CD6 is a 105–130 kDa surface glycoprotein expressed on the majority of T cells and a subset of B cells. The human cd6 gene maps to chromosome 11, and the expression of its protein product is tightly regulated. CD6 mediates cellular adhesion migration across the endothelial and epithelial cells. In a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alonso-Ramirez, Ruby, Loisel, Séverine, Buors, Caroline, Pers, Jacques-Olivier, Montero, Enrique, Youinou, Pierre, Renaudineau, Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3195340/ https://www.ncbi.nlm.nih.gov/pubmed/22076177 http://dx.doi.org/10.1155/2010/130646

Ejemplares similares

Anti-Fcgamma receptor (FcgammaR) autoantibodies (Ab) delay apoptosis of polymorphonuclear cells (PMN) in systemic autoimmune diseases by inducing the production of G-CSF and GM-CSF
por: Durand, V, et al.
Publicado: (2001)

The new B-cell-specific exon 1B of the CD5 mRNA favors autoimmunity by preventing the membrane expression of CD5
por: Renaudineau, Y, et al.
Publicado: (2003)

Disturbance of cytokine networks in Sjögren's syndrome
por: Youinou, Pierre, et al.
Publicado: (2011)

A new approach to comparing anti-CD20 antibodies: importance of the lipid rafts in their lytic efficiency
por: Hammadi, Mariam, et al.
Publicado: (2010)

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy
por: Bordron, Anne, et al.
Publicado: (2018)

Cell-free Fc-γ receptors IIIb, autoantibodies and related immune complexes trigger the production of G-CSF and GM-CSF in nonorgan-specific autoimmune diseases
por: Durand, V, et al.
Publicado: (2002)

Two promoters for the CD5 gene: one operating in T cells and activated B cells and another restricted to resting B cells
por: Renaudineau, Y, et al.
Publicado: (2002)

Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis
por: Seret, Guillaume, et al.
Publicado: (2012)

Neurological Disorders in Primary Sjögren's Syndrome
por: Tobón, Gabriel J., et al.
Publicado: (2012)

Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome
por: Cornec, Divi, et al.
Publicado: (2014)

Ultrasound assessment of salivary glands in patients with primary Sjögren’s syndrome treated with rituximab: Quantitative and Doppler waveform analysis
por: Jousse-Joulin, Sandrine, et al.
Publicado: (2007)

Therapeutic activity of two xanthones in a xenograft murine model of human chronic lymphocytic leukemia
por: Loisel, Séverine, et al.
Publicado: (2010)

Autoantibodies to Endothelial Cell Surface ATP Synthase, the Endogenous Receptor for Hsp60, Might Play a Pathogenic Role in Vasculatides
por: Alard, Jean-Eric, et al.
Publicado: (2011)

Epigenetics and autoimmune diseases: the X chromosome-nucleolus nexus
por: Brooks, Wesley H., et al.
Publicado: (2015)

Editorial: Epigenetic aspects of autoimmune diseases
por: Brooks, Wesley H., et al.
Publicado: (2022)

The contribution of epigenetics in Sjögren’s Syndrome
por: Konsta, Orsia D., et al.
Publicado: (2014)

Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies
por: Cornec, Divi, et al.
Publicado: (2014)

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
por: Mei, Henrik E, et al.
Publicado: (2012)

Hyposialylation Must Be Considered to Develop Future Therapies in Autoimmune Diseases
por: Bordron, Anne, et al.
Publicado: (2021)

Metabolic Program of Regulatory B Lymphocytes and Influence in the Control of Malignant and Autoimmune Situations
por: Iperi, Cristian, et al.
Publicado: (2021)

B cell-targeted therapies in autoimmunity: rationale and progress
por: Fiorina, Paolo, et al.
Publicado: (2009)

STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
por: Debant, Marjolaine, et al.
Publicado: (2019)

Is the blood B-cell subset profile diagnostic for Sjögren syndrome?
por: Binard, A, et al.
Publicado: (2009)

Abnormal B cell glycosylation in autoimmunity: A new potential treatment strategy
por: Morel, Marie, et al.
Publicado: (2022)

Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity
por: Taher, Taher E., et al.
Publicado: (2017)

Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis
por: Arvaniti, Pinelopi, et al.
Publicado: (2019)

Machine Learning for the Identification of a Common Signature for Anti–SSA/Ro 60 Antibody Expression Across Autoimmune Diseases
por: Foulquier, Nathan, et al.
Publicado: (2022)

Heterogeneity of antibody-secreting cells infiltrating autoimmune tissues
por: Giovannini, Diane, et al.
Publicado: (2023)

Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions
por: Cretenet, Gaspard, et al.
Publicado: (2016)

The role of anti-α-actinin antibodies in the pathogenesis and monitoring of lupus nephritis
por: Youinou, Pierre, et al.
Publicado: (2009)

The dual role of CD6 as a therapeutic target in cancer and autoimmune disease
por: Gurrea-Rubio, Mikel, et al.
Publicado: (2022)

Peripheral-blood b-cell subset disturbances in inflammatory joint diseases induced by Tropheryma whipplei
por: Le Goff, Maëlle, et al.
Publicado: (2019)

Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome
por: Le Goff, Maëlle, et al.
Publicado: (2017)

Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission
por: Dorcet, Guillaume, et al.
Publicado: (2023)

SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases
por: Larionova, Regina, et al.
Publicado: (2022)

Regulatory B Cells: An Exciting Target for Future Therapeutics in Transplantation
por: Nouël, Alexandre, et al.
Publicado: (2014)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade
por: Carvajal Alegria, Guillermo, et al.
Publicado: (2021)

Lupus Nephritis Risk Factors and Biomarkers: An Update
por: Renaudineau, Yves, et al.
Publicado: (2023)

Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study
por: Faguer, Stanislas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lrj8vlipviftq6arvu4rufcga1